Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Myelodysplastic Syndromes 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Anemia, Refractory, with Excess of Blasts 2Warts 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Seminoma 1Recurrence 1Neutropenia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Febrile Neutropenia 1Endodermal Sinus Tumor 1Carcinoma, Embryonal 1Breast Neoplasms 1Anemia, Refractory 1Agammaglobulinemia 1

Interventions

plerixafor 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Immunologic Deficiency Syndromes × Filgrastim × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡